Abstract
Protein kinases are enzymes that have a key regulatory role in cell biology involved in various cellular processes such as apoptosis, cell cycle, cytoskeletal rearrangement, immune response, nervous system function, and transcription. MARK3 protein kinase was identified as a marker for cancer, and proved to be overexpressed in head and neck cancer. With the aim of identifying possible active compounds able to perform interactions with the MARK3 protein binding site, active substructures known as scaffold were used in the process of similarity search. In this work, ligand-based virtual screening approaches were carried out to investigate potential novel MARK3 inhibitors. The obtained docking poses were rescored and after applying filters related to the physicochemical properties, as well as overlapping molecular interaction fields, toxicity prediction and prediction of biological activity spectra, three compounds were selected as the most promising and potential MARK3 inhibitors, with interest in head and neck cancer. Our results suggest that these molecules could be developed as novel lead compounds in anti-cancer drug design.
Keywords: Head and neck cancer, ligand-based virtual screening, MARK3, protein kinase, scaffold.
Graphical Abstract
Current Bioactive Compounds
Title:Ligand-Based Drug Design of Novel MARK-3 Inhibitors in Cancer
Volume: 10 Issue: 2
Author(s): Jonathan R. de Almeida, Josiana G. de Araujo Volpini, Joao G.C. Poiani, Carlton A. Taft and Carlos H.T. de Paula da Silva
Affiliation:
Keywords: Head and neck cancer, ligand-based virtual screening, MARK3, protein kinase, scaffold.
Abstract: Protein kinases are enzymes that have a key regulatory role in cell biology involved in various cellular processes such as apoptosis, cell cycle, cytoskeletal rearrangement, immune response, nervous system function, and transcription. MARK3 protein kinase was identified as a marker for cancer, and proved to be overexpressed in head and neck cancer. With the aim of identifying possible active compounds able to perform interactions with the MARK3 protein binding site, active substructures known as scaffold were used in the process of similarity search. In this work, ligand-based virtual screening approaches were carried out to investigate potential novel MARK3 inhibitors. The obtained docking poses were rescored and after applying filters related to the physicochemical properties, as well as overlapping molecular interaction fields, toxicity prediction and prediction of biological activity spectra, three compounds were selected as the most promising and potential MARK3 inhibitors, with interest in head and neck cancer. Our results suggest that these molecules could be developed as novel lead compounds in anti-cancer drug design.
Export Options
About this article
Cite this article as:
R. de Almeida Jonathan, G. de Araujo Volpini Josiana, G.C. Poiani Joao, A. Taft Carlton and de Paula da Silva Carlos H.T., Ligand-Based Drug Design of Novel MARK-3 Inhibitors in Cancer, Current Bioactive Compounds 2014; 10 (2) . https://dx.doi.org/10.2174/157340721002141001102743
DOI https://dx.doi.org/10.2174/157340721002141001102743 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
System Models, Assays and Endpoint Parameters to Evaluate Anticancer Compounds During Preclinical Screening
Current Medicinal Chemistry Cisplatin Is a DNA-Damaging Antitumour Compound Triggering Multifactorial Biochemical Responses in Cancer Cells: Importance of Apoptotic Pathways
Current Medicinal Chemistry - Anti-Cancer Agents Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Induction of Apoptosis by Curcumin and Its Implications for Cancer Therapy
Current Cancer Drug Targets Cytotoxic and Radio-sensitizing Effects of Polyphenolic Acetates in a Human Glioma Cell Line (BMG-1)
Current Pharmaceutical Design An Update on the Systemic Therapy of Malignant Salivary Gland Cancers: Role of Chemotherapy and Molecular Targeted Agents
Current Medicinal Chemistry - Anti-Cancer Agents Specific Targeted Therapy: A New Tool for the Destruction of Cancer
Current Drug Therapy Organ-Level Tissue Engineering Using Bioreactor Systems and Stem Cells: Implications for Transplant Surgery
Current Stem Cell Research & Therapy Free Flap Head and Neck Reconstruction After Cancer Therapy: Current State of the Art
Current Cancer Therapy Reviews CYP3A4-mediated Pharmacokinetic Interactions in Cancer Therapy
Current Drug Metabolism Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Applications of Molecular Imaging in Drug Discovery and Development Process
Current Pharmaceutical Biotechnology Platinum Compounds: A Hope for Future Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Prospects of Bacteriotherapy with Nanotechnology in Nanoparticledrug Conjugation Approach for Cancer Therapy
Current Medicinal Chemistry Novel Virally Targeted Therapies of EBV-Associated Tumors
Current Cancer Drug Targets Receptor Mediated Tumor Targeting: An Emerging Approach for Cancer Therapy
Current Drug Delivery Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic
Current Medicinal Chemistry Etiology of Neuroinflammatory Pathologies in Neurodegenerative Diseases: A Treatise
Current Psychopharmacology Concentrations of Cd, Cu, Pb and Zn in Blood Serum of Cancer Patients and Comparison with Healthy Person by Atomic Absorption Spectrometry
Current Analytical Chemistry Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed
Current Drug Targets